Sodium glucose cotransporter 2 inhibitors: place in diabetic nephropathy

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Metabolic and renal benefits of using sodium-glucose cotransporter type 2 inhibitors in patients with type 1 diabetes mellitus and continuous subcutaneous insulin infusion2024
2. 2Metabolic and cardio-renal benefits of SGLT2- inhibitors in diabetic patients2024
3. 3Clinical and laboratory factors associated with response to therapy with sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus2024
4. 4The role of COVID-19 in the development of diabetic nephropathy2024
5. 5Using a SGLT2 inhibitor does not modify the efficacy and tolerability of extended-release metformin in patients with type 2 diabetes2024